Future growth expectations in earnings/operating earnings/profits/EPS?

Biologicals business is in the investment phase with current revenue around $12 million; high growth expected over next 2-3 years with focus on scaling rather than margins now; profitability to follow as scale improves (Rajnish Sarna, p.18). Pharma segment is also in investment phase; profitability expected to materialize after 1 year as scale builds (Rajnish Sarna, p.12). CSM (Custom Synthesis & Manufacturing) segment faces softness in H1 FY26 but recovery expected from Q4 FY26; growth potentially single-digit in second half but full recovery not before H2 2026 or later (Rajnish Sarna & May

Current/ Expected Orderbook/ Pending Orders?

The current overall order book position stands at approximately $1.25 billion as of Q2 FY26. The company does not provide order book guidance broken down by specific fiscal years (e.g., FY26 or FY27). Demand normalization and inventory destocking in the global agrochemical industry are expected to improve order flow visibility from Q4 FY26. The management anticipates a recovery and positive growth trajectory in the second half of calendar year 2026. Order book growth is tied to market normalization and customer delivery schedules, with expectations of recovery over the next 2-3 quarters. No sp

Any current/future new fundraising through debt or equity?

The company currently has a strong cash position and is not in a hurry to deploy available cash. They are actively evaluating several inorganic opportunities domestically and internationally, including technology areas outside India. There is no specific mention of planned fundraising through debt or equity in the near term. The company prefers to sit on cash and wait for the right set of opportunities rather than raising funds immediately.

Any current/future capex/capital investment/strategic investment?

The company is actively investing in its Pharma CRDMO platform, focusing on capability-building, people, processes, and planned upgrades/additions to assets to support strategic growth. In electronic chemicals, there are two dedicated plants: one near commissioning and another multi-product plant, indicating ongoing capex in this segment. Biologicals business is currently in the investment phase, including market and product development across the US, Brazil, Europe, Mexico, and India, along with commissioning a new biological research center in Hyderabad. The company is evaluating several ino

Future growth expectations in sales/revenue/volumes?

Biologicals business is a global long-term play currently in the investment phase with ~$12 million revenue; expected to grow at a high rate over next 2-3 years before profitability improves. Biologicals have been growing at double-digit rates and expected to continue as a key growth driver over next 5-10 years. Pharma business showed 54% Y-o-Y growth in H1 FY26; despite biotech funding slowdown, long-term positive outlook with capability building ongoing. AgChem exports experienced volume-led decline but new products grew 38% Y-o-Y in H1 FY26; 8-10 new molecules planned for commercializ

IN US

Sale is live|00:00:00left today

P I Industries LtdQ3 FY25Fertilizers & Agrochemicals

P I Industries Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,755P/E: 34.6Market Cap: ₹47.3K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Biologicals business is a global long-term play currently in the investment phase with ~$12 million revenue; expected to grow at a high rate over next 2-3 years before profitability improves.
→Biologicals have been growing at double-digit rates and expected to continue as a key growth driver over next 5-10 years.
→Pharma business showed 54% Y-o-Y growth in H1 FY26; despite biotech funding slowdown, long-term positive outlook with capability building ongoing.
→AgChem exports experienced volume-led decline but new products grew 38% Y-o-Y in H1 FY26; 8-10 new molecules planned for commercialization this fiscal.
→Domestic business impacted by erratic rainfall and regulatory changes but expected positive trajectory in H2, especially with improved Rabi season outlook.
→Overall industry demand expected to normalize and recover by Q4 FY26 with gradual normalization of inventories.
→Long-term growth outlook remains intact, focusing on sustainable expansion across Ag Sciences, Pharma CRDMO, Specialty Chemicals, and biologicals.

Margin guidance

Category 3

→Biologicals business is in the investment phase with current revenue around $12 million; high growth expected over next 2-3 years with focus on scaling rather than margins now; profitability to follow as scale improves (Rajnish Sarna, p.18).
→Pharma segment is also in investment phase; profitability expected to materialize after 1 year as scale builds (Rajnish Sarna, p.12).
→CSM (Custom Synthesis & Manufacturing) segment faces softness in H1 FY26 but recovery expected from Q4 FY26; growth potentially single-digit in second half but full recovery not before H2 2026 or later (Rajnish Sarna & Mayank Singhal, pp.16,7).
→Overall, short-term headwinds exist due to climatic and market conditions; however, medium to long-term growth outlook remains positive with expectation to regain momentum in coming years (Mayank Singhal & Sanjay Agarwal, pp.6,4).
→EBITDA margins to remain resilient with annual margin guidance maintained despite short-term variability (Mayank Singhal, p.9).

3 more insights locked — sign up free to unlock

Fundraise plans

→The company currently has a strong cash position and is not in a hurry to deploy available cash.
→They are actively evaluating several inorganic opportunities domestically and internationally, including technology areas outside India.
→There is no specific mention of planned fundraising through debt or equity in the near term.
→The company prefers to sit on cash and wait for the right set of opportunities rather than raising funds immediately.

Order book

→The current overall order book position stands at approximately $1.25 billion as of Q2 FY26.
→The company does not provide order book guidance broken down by specific fiscal years (e.g., FY26 or FY27).
→Demand normalization and inventory destocking in the global agrochemical industry are expected to improve order flow visibility from Q4 FY26.
→The management anticipates a recovery and positive growth trajectory in the second half of calendar year 2026.
→Order book growth is tied to market normalization and customer delivery schedules, with expectations of recovery over the next 2-3 quarters.
→No specific order book size forecast for FY27 is provided currently, as it remains too early for clear guidance.

Capex plans

Yes

→The company is actively investing in its Pharma CRDMO platform, focusing on capability-building, people, processes, and planned upgrades/additions to assets to support strategic growth.
→In electronic chemicals, there are two dedicated plants: one near commissioning and another multi-product plant, indicating ongoing capex in this segment.
→Biologicals business is currently in the investment phase, including market and product development across the US, Brazil, Europe, Mexico, and India, along with commissioning a new biological research center in Hyderabad.
→The company is evaluating several inorganic opportunities domestically and internationally but is cautious due to market uncertainties and is willing to hold cash while seeking the right opportunities.
→No specific quantitative capex figures were disclosed for these investments.

How does P I Industries Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1P I Industries Ltd

Rev 4Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like P I Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio